Ovarian Cancer | Meet The Professor: Optimizing the Management of Ovarian Cancer — Part 2 of a 4-Part Series
Featuring perspectives from Dr David M O’Malley, including the following topics: Introduction: 2023 American Oncology Network Summit (0:00) Case: A woman in her late 70s with metastatic BRCA wild-type, homologous recombination deficiency-negative high-grade serous ovarian cancer (HGSOC) experiences disease progression after 6 lines of systemic therapy; PS = 0 — Dana M Chase, MD (8:31) Case: A woman in her mid 80s is diagnosed with a germline BRCA2 (gBRCA2) mutation and Stage IV HGSOC; CA-125 32,000 U/mL — Mamta Choksi, MD (21:27) Case: A woman in her mid 40s who has undergone TAH/BSO for Stage IC HGSOC with a gBRCA2 mutation receives adjuvant carboplatin/paclitaxel — Priya Rudolph, MD, PhD (32:47) Case: A woman in her early 60s with a gBRCA1 mutation and HGSOC who has undergone debulking surgery and carboplatin/paclitaxel develops anemia on maintenance olaparib — Karim ElSahwi, MD (40:56) Case: A woman in her mid 60s with recurrent BRCA wild-type HGSOC is enrolled in a trial of tumor treating fields and paclitaxel — Lyndsay J Willmott, MD (54:01) Case: A woman in her early 50s with multiregimen-recurrent FR-alpha-positive OC and a gBRCA1 mutation receives mirvetuximab soravtansine — Kellie E Schneider, MD (58:50) CME information and select publications